Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial

Authors:

Abstract
No abstract available
Funding Information
  • Innovent Biologics

This publication has 30 references indexed in Scilit: